Article Text

Download PDFPDF

Reduction in arterial stiffness and vascular age by naltrexone-induced interruption of opiate agonism: a cohort study
  1. Albert Stuart Reece,
  2. Gary Kenneth Hulse
  1. Unit for Research and Education in Alcohol and Drugs, School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Perth, Western Australia, Australia
  1. Correspondence to Dr Albert Stuart Reece; sreece{at}bigpond.net.au

Abstract

Objective To prospectively assess if opiate antagonist treatment or the opiate-free status could reverse opiate-related vasculopathy.

Design Longitudinal Open Observational, Serial ‘N of One’, over 6.5 years under various treatment conditions: opiate dependence, naltrexone and opiate-free.

Setting Primary care, Australia.

Participants 20 opiate-dependent patients (16 males: 16 cases of buprenorphine 4.11±1.17 mg, two of methadone 57.5±12.5 mg and two of heroin 0.75±0.25 g).

Intervention Studies of central arterial stiffness and vascular reference age (RA) were performed longitudinally by SphygmoCor Pulse Wave Analysis (AtCor, Sydney).

Primary outcomes Primary outcome was vascular age and arterial stiffness accrual under different treatment conditions.

Results The mean chronological age (CA) was 33.62±2.03 years. The opiate-free condition was associated with a lower apparent vascular age both in itself (males: p=0.0402 and females: p=0.0360) and in interaction with time (males: p=0.0001 and females: p=0.0004), and confirmed with other measures of arterial stiffness. The mean modelled RA was 38.82, 37.73 and 35.05 years in the opiate, naltrexone and opiate-free conditions, respectively. The opiate-free condition was superior to opiate agonism after full multivariate adjustment (p=0.0131), with modelled RA/CA of 1.0173, 0.9563 and 0.8985 (reductions of 6.1% and 11.9%, respectively).

Conclusions Data demonstrate that opiate-free status improves vascular age and arterial stiffness in previous chronic opiate users. The role of opiate antagonist treatment in achieving these outcomes requires future clarification and offers hope of novel therapeutic remediation.

  • Cardiology
  • Toxicology
  • Therapeutics
  • opiates
  • naltrexone
  • reversal

This is an open-access article distributed under the terms of the creative commons attribution non-commercial license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. see: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.